Eli Lilly: Q4 beats consensus

(CercleFinance.com) - Eli Lilly reported better-than-expected Q4 results on Thursday, and provided forecasts for 2025 that exceeded market expectations.


This morning, the US pharmaceutical group reported a more than doubling of net income to $4.4bn, or $4.88 per share, double the $2.2bn, or $2.32 per share, in Q4 2023.

Excluding non-recurring items (non-GAAP), EPS reached $5.32, well above the consensus target of $5.08.

Sales jumped by 45% to over $13.5bn, again exceeding the consensus of $13.4bn.

Sales volumes soared by 48%, driven by its diabetes and obesity treatments Mounjaro and Zepbound, more than offsetting a negative price effect of 4%.

For 2025, the Indianapolis (Indiana)-based laboratory is forecasting earnings per share of between $22.05 and $23.55, on expected sales of between $58bn and $61bn, with average estimates exceeding those currently established by consensus.


Copyright (c) 2025 CercleFinance.com. All rights reserved.